Eutilex

At a glance

Eutilex filed 91 disclosures in the last 12 months, including 3 5% holder, 2 contract and 1 insider. The most recent key filing was on Jan 20: A major holder's stake rose from 7.03% to 7.03%.

Revenue for 2025 was ₩10.3B, up 8.1% on 2024. It made an operating loss of ₩18.9B. Debt was 161% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.8B and operating loss of ₩4.7B.

The 2025 annual report lists 119 employees with an average tenure of 2.6 years and average pay of ₩55.5M, #1423 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩160.4M each on average. It paid no cash dividend for 2025. Zhejiang Huahai Pharmaceutical Co.,LTD. and related parties held 14.12% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 7.03% on Jan 20.

From the 2025 annual report

Staff: 119, of whom 0 on fixed-term contracts. Total pay for the year: ₩6.6B. Directors and auditors: 5, paid ₩802.1M in total.

No cash dividend was paid for 2025.

Largest shareholder

Zhejiang Huahai Pharmaceutical Co.,LTD. holds 7.83%; with 5 related parties the group holds 14.12% of common shares at year end (from 29.70% at the start of the year).

Auditor: 삼정회계법인 · opinion: Disclaimer of opinion.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

2 new supply contracts worth 26% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports